ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS LawBusiness Wire · 1 day ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERASPRNewsWire · 2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERASGlobeNewsWire · 4 days ago
Erasca (NASDAQ:ERAS) Shares Down 5.8% – What’s Next?Defense World · 6 days ago
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your BehalfGlobe News Wire · Oct 15, 2026
Erasca: Revolution's Approval Just Took Risk Out Of The Fast FollowerSeeking Alpha · Oct 5, 2026Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.11 | -$0.14 | Miss |
| May 11, 2026 | -$0.11 | -$0.60 | Miss |
| Mar 12, 2026 | -$0.11 | -$0.10 | Beat |
| Nov 12, 2025 | -$0.11 | -$0.11 | Beat |
| Aug 12, 2025 | -$0.12 | -$0.12 | Beat |
| May 13, 2025 | -$0.12 | -$0.11 | Beat |